COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics to Highlight Genetic Testing Advancements at 2025 National Society of Genetic Counselors Annual Conference
06/11/2025
SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share 11 new research studies highlighting [...]
Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
06/11/2025
Rising Demand from Third-Party Diagnostic and Biotechnology Companies Drives CDMO Service Expansion Comprehensive CDMO services now featured on Biomerica’s updated website IRVINE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE [...]
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025
06/11/2025
FLORHAM PARK, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
06/11/2025
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a [...]
Cytrellis Secures FDA Clearance for Full Body Resurfacing Using Ellacor® Micro-Coring® Technology
06/11/2025
New indication significantly expands applications for ellacor to treat sagging skin on body areas outside of the face WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cytrellis Biosystems, Inc. (“Cytrellis” or the “ [...]
Noom Unveils New Diabetes Lifestyle Program and Predictive Glucose Forecasting to Tackle America’s Diabetes Crisis
06/11/2025
Innovative tools give employers, health plans, and individuals proactive ways to prevent and manage diabetes—one of the nation’s fastest-growing and most costly chronic conditions PRINCETON, N.J., Nov. 06, 2025 (GLOBE [...]
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
06/11/2025
Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated [...]
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion
06/11/2025
Higher reimbursement, regulatory clarity, and acknowledgment of future indication expansion expected to reinforce physician confidence and support continued expansion HORSHAM, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- [...]
Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy
06/11/2025
- Innovation Passport award facilitates accelerated time to market and helps expedite patient access to transformative new medicines - - New Innovative Licensing and Access Pathway (ILAP) designation provides unique, [...]
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
06/11/2025
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data Provides Insights on [...]
Dentsply Sirona Reports Third Quarter 2025 Results
06/11/2025
Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buy GAAP gross [...]
Immunocore reports third quarter financial results and provides a business update
06/11/2025
Immunocore reports third quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on track to [...]
ProQR Announces Third Quarter 2025 Operating and Financial Results
06/11/2025
Received CTA authorization for Phase 1 trial of lead program AX-0810, targeting NTCP for cholestatic diseases Initiating Phase 1 study of AX-0810 in healthy volunteers, with initial safety, tolerability, and PK data [...]
TREOS Bio Announces Publication of Phase 1b Clinical Trial Results of PolyPEPI1018 Plus TAS-102 in Refractory MSS mCRC in JCO Oncology Advances
06/11/2025
First study to report promising activity for an active immunotherapy combined with TAS-102 (LONSURF®) in late-stage MSS mCRC; TREOS advances Phase II programme with Charité – Universitätsmedizin Berlin and Junshi [...]
American Shared Hospital Services Announces Third Quarter Financial Results Conference Call
06/11/2025
Call Scheduled for November 13 th at 1:00 PM ET SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery [...]
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
06/11/2025
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and [...]
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
06/11/2025
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABA A α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage [...]
Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
06/11/2025
Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead [...]
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
06/11/2025
Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of [...]

Pages